Drug Database
RA

rabbit anti-T-lymphocyte immune globulin (Zetbulin)

✓ Approved

Nippon Zoki · 多克隆抗体 · 多克隆抗体

什么是 rabbit anti-T-lymphocyte immune globulin?

rabbit anti-T-lymphocyte immune globulin 是一种多克隆抗体,由Nippon Zoki研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名Zetbulin
公司Nippon Zoki
药物类别多克隆抗体, 抗体
给药途径Injectable (Others), Intravenous (IV)
状态Approved

治疗适应症

rabbit anti-T-lymphocyte immune globulin 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Blood and lymphatic system disordersAplastic anaemia✓ Approved

相关研究文献

PubMedRheumatology (Oxford, England)2026-11-19

Distinct clinical-immunological subtypes define prognostic heterogeneity in anti-U1RNP-positive connective tissue diseases.

Liu Di D, Zhang Jingyi J, Zhang Jing J, Hu Nan N et al.

Anti-U1 ribonucleoprotein (U1RNP) antibody-positive connective tissue diseases (CTDs) exhibit marked clinical heterogeneity that is not adequately captured by conventional diagnostic classifications. This study aimed to identify intrinsic clinical-immunological subtypes and assess their prognostic implications. In this single-center retrospective cohort, 358 patients with anti-U1RNP-positive CTDs were analyzed using multiple correspondence analysis and hierarchical clustering. Key discriminative features were identified through least absolute shrinkage and selection operator (LASSO) regression. Peripheral blood lymphocyte subsets were assessed by flow cytometry, and long-term survival was compared using Kaplan-Meier analysis. Clustering analysis identified three clinical-immunological subtypes with significant differences. Cluster 1, the "mild immunological type", was characterized by minimal autoantibody positivity and relatively normal lymphocyte counts, and exhibited the most favorable prognosis. Cluster 2, the "exocrine gland-joint-muscle involvement type", presented with prominent sicca symptoms, arthralgia, elevated creatine kinase (CK), and interstitial lung disease (ILD), and had an intermediate prognosis. Cluster 3, the "severe systemic type", was associated with marked pericarditis, renal injury, multiple autoantibody positivity, and widespread lymphopenia, and had the poorest survival. LASSO analysis highlighted normal T lymphocyte and T follicular helper cell counts for cluster 1, elevated CK and rheumatoid factor for cluster 2, and anti-dsDNA/anti-nucleosome antibodies, elevated D-dimer, and major organ involvement for cluster 3. Anti-U1RNP-positive CTDs comprise distinct clinical-immunological subtypes with different clinical features, immune profiles, and prognostic outcomes. Subtype-based stratification may facilitate precision management, particularly for patients with multiple autoantibody positivity and severe lymphopenia who are at high risk of poor prognosis.

PMID 43053294
阅读全文 →
PubMedCancer immunology, immunotherapy : CII2026-11-19

Tumor-associated antigen-reactive T cells and clinical outcomes in head and neck squamous cell carcinoma treated with pembrolizumab plus chemotherapy.

Sato Ryosuke R, Sakaue Shota S, Ominato Hisataka H, Inoue Takahiro T et al.

Blood-based biomarkers associated with clinical outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with pembrolizumab plus chemotherapy remain poorly defined. We investigated 38 patients with HNSCC treated with pembrolizumab plus 5-fluorouracil and platinum (FP). Baseline systemic inflammation and immune status were assessed using routine laboratory parameters. Peripheral blood mononuclear cells were analyzed by flow cytometry to assess exhaustion- and activation-associated markers on CD4⁺ and CD8⁺ T cells, including CD38, Tim-3, PD-1, and ICOS. Tumor-associated antigen (TAA)-reactive immune responses were evaluated by interferon-γ production following stimulation with epidermal growth factor receptor (EGFR)- and c-Met-derived peptides. PD-L1 CPS positivity, elevated neutrophil-to-lymphocyte ratio, and higher frequencies of CD8⁺CD38⁺ T cells were associated with clinical outcomes, with similar trends observed for selected inflammatory and peripheral T-cell activation/exhaustion-associated markers. Tumor-associated antigen-reactive immune responses were detected in a subset of patients and were associated with prolonged progression-free survival, while EGFR peptide reactivity was additionally associated with improved overall survival. In this exploratory study, immune reactivity to TAAs was associated with favorable clinical outcomes in patients receiving pembrolizumab plus FP. Together with systemic inflammation and peripheral T-cell activation/exhaustion markers, these findings support further evaluation of integrated blood-based immune profiling, including TAA-reactive immune responses, as candidate biomarkers in larger prospective cohorts.

PMID 43052553
阅读全文 →
PubMedNature communications2026-11-19

Fatty acids in the tumor microenvironment reprogram neutrophils to induce adenosine-mediated immunosuppression in mice.

Singhal Rashi R, Zhang Nina W NW, Lee Zheng Hong ZH, Bell Hannah N HN et al.

As solid tumors progress, the tumor microenvironment becomes increasingly immunosuppressive, impairing cytotoxic T-cell activity and limiting the efficacy of immune checkpoint blockade. However, the mechanistic drivers of this immunosuppression remain poorly understood. Here, we identify a tumor-derived lipid-neutrophil-adenosine axis as a critical regulator of immune suppression in advanced colorectal cancer (CRC). We show that fatty acids enriched in tumor interstitial fluid reprogram neutrophils toward an immunosuppressive phenotype through PPARα activation, upregulation of CD39 and CD73, and adenosine generation, ultimately leading to T-cell suppression. AB928, a dual A2aR/A2bR adenosine receptor antagonist currently in clinical trials, restores T-cell proliferation, effector function, and tumor-killing capacity in vitro and in vivo. Importantly, AB928 synergizes with anti-PD-1 therapy to enhance survival in an immunotherapy-resistant autochthonous model of metastatic CRC. Thus, our findings define a metabolic immune evasion mechanism in the microenvironment and provide a rationale for targeting neutrophil-derived adenosine signaling to improve immunotherapy responses in CRC.

PMID 43052331
阅读全文 →
PubMedSmall (Weinheim an der Bergstrasse, Germany)2026-11-19

eQt Protein Nanocage-Delivered IL-21 mRNA Systemically Reprograms Host Immune Cells Toward Stemness and Maturation to Achieve Anti-Tumor Immunity.

Shen Ruitong R, Zhang Jinsong J, Zhang Huan H, Liu Jinsong J et al.

Effective cancer immunotherapy requires reprogramming host immunity toward stem-like states. However, clinical use of IL-21 is limited by short half-life and toxicity. Here, we develop a bio-inspired protein nanocage platform (eQt) that encapsulates IL-21 mRNA via high-affinity λN-boxB interactions during bacterial biosynthesis, enabling one-step manufacturing and pH-responsive endosomal release. eQt-IL-21 drives dendritic cell maturation, characterized by marked upregulation of CD80 and CD86, and transcriptome-wide enrichment of MHC-I antigen processing and presentation pathways (H2-K1, H2-D1, B2m, Tap2), establishing a highly stimulatory environment for T cell priming. Transcriptomic profiling of draining lymph nodes reveals that eQt-IL-21 preferentially diverts CD8+ T-cell differentiation away from terminal exhaustion toward a TCF-1+/CCR7+ stem-like progenitor identity, with concordant upregulation of Tcf7, Sell (encoding CD62L), and LEF-1, sustaining a self-renewing memory reservoir and long-lived central memory T cells (Tcm). In preclinical E.G7-OVA models, this immunological reprogramming translates into potent prophylactic efficacy and durable therapeutic remission of established tumors, without detectable systemic toxicity. This work establishes IL-21 mRNA-mediated immune-cell reprogramming as a mechanistic cornerstone of durable anti-tumor immunity, and positions the eQt nanocage as a versatile, scalable platform for precision cancer immunotherapy.

PMID 43053577
阅读全文 →
PubMedNature communications2026-11-19

Oncogenic signalling and host immunocompetency govern senescent cell clearance and systemic inflammation in a mouse model of oncogene-induced senescence.

Colleoni Cristina C, Ormoli Leonardo L, Gallina Pierangela P, Rudilosso Laura L et al.

Senescence is a stress-induced program defined by permanent cell-cycle arrest and a pro-inflammatory senescence-associated secretory phenotype (SASP). Defective clearance of senescent cells promotes inflammation, tissue dysfunction, and ageing, yet determinants of their elimination remain poorly understood. Here, we model oncogene-induced senescence in the hematopoietic system by transplanting BrafV600E- or BrafΔN-expressing hematopoietic stem and progenitor cells into recipients with distinct immune backgrounds. BrafV600E induces a stronger senescence program and more aggressive disease than BrafΔN. Survival depends on oncogene-expressing cell burden and host immunity: immunocompetent, lower-burden mice clear oncogene-expressing cells and survive long-term, whereas higher-burden mice show checkpoint upregulation, T-cell exhaustion, and early death. NSG, Rag1KO, and lymphocyte-depleted hosts fail to clear these cells, developing sustained inflammation and bone marrow failure. Rapamycin administration attenuates senescence-associated features and improves survival. These findings identify oncogenic intensity and adaptive immune competence as coupled determinants of senescent-cell fate, with implications for chronic inflammation and senescence-targeted therapies.

PMID 43052285
阅读全文 →
PubMedBMC musculoskeletal disorders2026-11-19

The role of immune-inflammatory biomarkers in diagnosing infected nonunion among nonunion patients after repair of extremity fractures.

Wang Zhen Z, Mao Haijun H, Xu Guangyue G, Zhu Zezhang Z

We aimed to assess the diagnostic accuracy of various biomarkers, such as the systemic immune-inflammation index (SII), inflammatory burden index (IBI), pan-immune inflammation value (PIV), and systemic inflammatory response index (SIRI), in cases of infected nonunion after repair of extremity fractures. In this retrospective analysis of patients who underwent internal fixation surgery with open reduction for extremity fractures between January 2015 and June 2024, the following information was evaluated at admission: age, sex, clinical features, erythrocyte sedimentation rate (ESR), white blood cell (WBC) count, platelet count (PC), C-reactive protein (CRP) level, monocyte count (MC), lymphocyte count (LC), neutrophil count (NC), monocyte-lymphocyte ratio (MLR), neutrophil-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), SII, IBI, SIRI, and PIV. Receiver operating characteristic (ROC) curves, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (LR+) and negative likelihood ratio (LR-) were constructed to compare the diagnostic performance of SII, IBI, SIRI, and PIV with other known serum markers. The study population consisted of 279 patients, of which 66 (23.7%) showed infected nonunion on the basis of the FRI consensus definition. All blood biomarkers were significantly different in patients with infected nonunion than in those with aseptic nonunion (p < 0.01). ROC analysis revealed that SII, PIV, IBI, and SIRI outperformed any other marker in diagnosing infected nonunion with the area under the curve (AUC) values more than 0.8. PIV showed the highest AUC value (0.823; 95% CI: 0.764-0.882), the highest sensitivity, specificity, and NPV (86.36%, 73.71% and 94.58%, respectively), and an optimal cutoff value of > 532.35. IBI had the highest LR+ with 3.84. PIV had the lowest LR- with 0.19. The SII, PIV, IBI, and SIRI showed potential for diagnosing infected nonunion. Whether SII, PIV, IBI, and SIRI can be regarded as a promising diagnostic indicator requires more studies.

PMID 43052925
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多rabbit anti-T-lymphocyte immune globulin